Spyre Therapeutics (SYRE) Stock Price, News & Analysis

Company Overview

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts. The company utilizes advanced screening technologies and a modular engineering approach to optimize therapeutic candidates, streamline preclinical development and position its programs for clinical readiness.

Based in the United States, Spyre Therapeutics operates a modern research and development facility that supports both in-house projects and external partnerships. Led by a management team experienced in biopharmaceutical innovation and development, the company is working to advance its lead programs into human trials and aims to bring new treatment options to patients with high-need cancers.

Key Stats

• Today's Range: $70.21 to $73.21
• 50-Day Range: $39.89 to $74.45
• 52-Week Range: $12.28 to $76.00
• Volume: 2.01 million shs
• Average Volume: 1.51 million shs
• Market Capitalization: $5.59 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $85.08
• Consensus Rating: Buy

Spyre Therapeutics Stock Analysis - MarketRank™

Spyre Therapeutics scored higher than 54% of companies evaluated by MarketBeat, and ranked 419th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Buy

Consensus Rating

Spyre Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 10 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Spyre Therapeutics has a consensus price target of $85.08, representing about 19.8% upside from its current price of $71.01.

Amount of Analyst Coverage

Spyre Therapeutics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Spyre Therapeutics are expected to decrease in the coming year, from ($2.80) to ($2.88) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Spyre Therapeutics is -34.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Spyre Therapeutics is -34.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Spyre Therapeutics has a P/B Ratio of 9.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

17.57% of the float of Spyre Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Spyre Therapeutics has a short interest ratio ("days to cover") of 7.35.

Change versus previous month

Short interest in Spyre Therapeutics has recently increased by 11.85%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Spyre Therapeutics does not currently pay a dividend.

Dividend Growth

Spyre Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 0.43

News Sentiment

Spyre Therapeutics has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 20 news articles for Spyre Therapeutics this week, compared to 4 articles on an average week.

Search Interest

30 people have searched for SYRE on MarketBeat in the last 30 days. This is an increase of 900% compared to the previous 30 days.

MarketBeat Follows

10 people have added Spyre Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.

Company Ownership

• Score: 2.0 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Spyre Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,805,860.00 in company stock.

Percentage Held by Insiders

15.69% of the stock of Spyre Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

80.39% of the stock of Spyre Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SYRE Stock Analysis - Frequently Asked Questions

How have SYRE shares performed this year?

Spyre Therapeutics' stock was trading at $32.76 at the start of the year. Since then, SYRE stock has increased by 116.8% and is now trading at $71.01.

How were Spyre Therapeutics' earnings last quarter?

Spyre Therapeutics, Inc. (NASDAQ:SYRE) posted its quarterly earnings data on Tuesday, May, 5th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.66) by $0.08.

When did Spyre Therapeutics IPO?

Spyre Therapeutics (SYRE) raised $85 million in an IPO on Wednesday, April 6th 2016. The company issued 5,000,000 shares at $16.00-$18.00 per share.

Who are Spyre Therapeutics' major shareholders?

Spyre Therapeutics' top institutional investors include Emerald Advisers LLC (0.78%), Candriam S.C.A. (0.77%), Pictet Asset Management Holding SA (0.62%) and Emerald Mutual Fund Advisers Trust (0.52%). Insiders that own company stock include Cameron Turtle, Scott L Burrows, Sheldon Sloan and Jeffrey W Albers.
View institutional ownership trends.

How do I buy shares of Spyre Therapeutics?

Shares of SYRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Spyre Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Spyre Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET).

Company Calendar

• Today: 5/05/2026
• Last Earnings: 5/05/2026
• Next Earnings (Estimated): 5/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SYRE
• Previous Symbol: NASDAQ:SYRE
• CIK: 1636282
• Web: www.aeglea.com
• Phone: 512-942-2935
• Fax: 512-872-5121
• Employees: 73
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Spyre Therapeutics: $85.08
• High Price Target: $106.00
• Low Price Target: $53.00
• Potential Upside/Downside: +19.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.08)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$155.20 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -41.79%
• Return on Assets: -25.97%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 13.25
• Quick Ratio: 13.25

Sales & Book Value

• Annual Sales: $890 thousand
• Price / Sales: 6,285.58
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.21 per share
• Price / Book: 9.85

Miscellaneous

• Outstanding Shares: 78,780,000
• Free Float: 66,423,000
• Market Cap: $5.59 billion
• Optionable: Optionable
• Beta: 3.12